<?xml version="1.0" encoding="UTF-8"?>
<p id="para100">Given the poor outcomes associated with CHOP as front-line therapy in peripheral T-cell lymphoma and the promising data in relapsing and refractory peripheral T-cell lymphoma with GEM-P, the UK National Cancer Research Institute (NCRI) Lymphoma Clinical Study Group started the CHEMO-T trial in 2012 to investigate the potential superiority of GEM-P compared with CHOP in previously untreated patients with peripheral T-cell lymphoma.</p>
